Payment overview · 2025
General Payments
$94.25
5 reported records · 3 companies
Healthcare provider profile · identity verified
William Lee Harris, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLESTON, WV · NPI 1821162207
Verified facts
What the public records show
CMS Open Payments records show William Lee Harris, M.D. received $94.25 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 36.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.01 | 36.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.80 | 35.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.44 | 28.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.25 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.01 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.01 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 896 | 105 |
| Alprazolam | Alprazolam | 584 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 535 | 149 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 487 | 40 |
| Omeprazole | Omeprazole | 458 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 134 |
| Potassium Chloride | Potassium Chloride | 392 | 132 |
| Metoprolol Succinate | Metoprolol Succinate | 337 | 100 |
| Lisinopril | Lisinopril | 331 | 98 |
| Furosemide | Furosemide | 309 | 108 |
| Pravastatin Sodium | Pravastatin Sodium | 306 | 84 |
| Losartan Potassium | Losartan Potassium | 305 | 92 |
| Valsartan | Valsartan | 304 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 91 |
| Simvastatin | Simvastatin | 286 | 86 |
| Azithromycin | Azithromycin | 272 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 79 |
| Metformin Hcl Er | Metformin Hcl | 253 | 82 |
| Lorazepam | Lorazepam | 231 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 65 |
| Gabapentin | Gabapentin | 203 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 62 |
| Eliquis | Apixaban | 182 | 53 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 173 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 32 |
| Cephalexin | Cephalexin | 161 | 85 |
| Ezetimibe | Ezetimibe | 156 | 48 |
| Glimepiride | Glimepiride | 154 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 47 |
| Meloxicam | Meloxicam | 144 | 51 |
| Allopurinol | Allopurinol | 143 | 45 |
| Tramadol Hcl | Tramadol Hcl | 142 | 44 |
| Amoxicillin | Amoxicillin | 140 | 69 |
| Cefuroxime | Cefuroxime Axetil | 137 | 75 |
| Methylprednisolone | Methylprednisolone | 137 | 114 |
| Clonidine Hcl | Clonidine Hcl | 131 | 36 |
| Metformin Hcl | Metformin Hcl | 124 | 35 |
| Sertraline Hcl | Sertraline Hcl | 123 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 90 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 118 | 32 |
| Donepezil Hcl | Donepezil Hcl | 117 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 115 | 37 |
| Spironolactone | Spironolactone | 113 | 33 |
| Temazepam | Temazepam | 113 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 31 |
| Trazodone Hcl | Trazodone Hcl | 108 | 32 |
| Colestipol Hcl | Colestipol Hcl | 106 | 30 |
| Mounjaro | Tirzepatide | 105 | 16 |
| Famotidine | Famotidine | 103 | 40 |
| Clonazepam | Clonazepam | 98 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 49 |
| Synthroid | Levothyroxine Sodium | 89 | 24 |
| Finasteride | Finasteride | 88 | 27 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 85 | 24 |
| Felodipine Er | Felodipine | 85 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 85 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 24 |
| Terbinafine Hcl | Terbinafine Hcl | 82 | 20 |
| Atenolol | Atenolol | 78 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 76 | 44 |
| Januvia | Sitagliptin Phosphate | 76 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 22 |
| Carvedilol | Carvedilol | 74 | 22 |
| Mirtazapine | Mirtazapine | 74 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | suppressed |
| Indapamide | Indapamide | 68 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 15 |
| Meclizine Hcl | Meclizine Hcl | 64 | 17 |
| Montelukast Sodium | Montelukast Sodium | 63 | 20 |
| Gemfibrozil | Gemfibrozil | 62 | 18 |
| Methocarbamol | Methocarbamol | 60 | 24 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 59 | 27 |
| Fenofibrate | Fenofibrate | 58 | 15 |
| Xarelto | Rivaroxaban | 57 | 15 |
| Fluconazole | Fluconazole | 56 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 25 |
| Valacyclovir | Valacyclovir Hcl | 56 | 26 |
| Celecoxib | Celecoxib | 55 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 25 |
| Betamethasone Valerate | Betamethasone Valerate | 54 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 51 | 17 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 29 |
| Tradjenta | Linagliptin | 49 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 14 |
| Pregabalin | Pregabalin | 46 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 13 |
| Warfarin Sodium | Warfarin Sodium | 45 | 15 |
| Buspirone Hcl | Buspirone Hcl | 44 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 12 |
| Diazepam | Diazepam | 43 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 43 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Ozempic | Semaglutide | 43 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 12 |
| Torsemide | Torsemide | 43 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 42 | 11 |
| Prednisone | Prednisone | 42 | suppressed |
| Estradiol | Estradiol | 41 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | 12 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Acarbose | Acarbose | 35 | 13 |
| Colesevelam Hcl | Colesevelam Hcl | 35 | 11 |
| Febuxostat | Febuxostat | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 17 |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 33 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Kerendia | Finerenone | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | 11 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Niacin Er | Niacin | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Naproxen | Naproxen | 25 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | 14 |
| Fentanyl | Fentanyl | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Trimethoprim | Trimethoprim | 19 | suppressed |
| Colchicine | Colchicine | 18 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Mesalamine Er | Mesalamine | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 13 | 12 |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.25 · 5 records | Novo Nordisk Inc | Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error